Tutte le immagini(1)

Documenti

CdO/CdA

A9522

Anti-Antithrombin III antibody produced in rabbit

Name: Anti-Antithrombin III antibody produced in rabbit
Brand: SIGMA

fractionated antiserum, lyophilized powder

Sinonimo/i:

Anti-AT3

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Tutte le immagini(1)

About This Item

Numero MDL:

MFCD00162398

Codice UNSPSC:

12352203

NACRES:

NA.41

Origine biologica

rabbit

Livello qualitativo

200

Coniugato

unconjugated

Forma dell’anticorpo

fractionated antiserum

Tipo di anticorpo

primary antibodies

Clone

polyclonal

Forma fisica

lyophilized powder

Reattività contro le specie

human

Confezionamento

vial of 2 mL lyophilized antiserum

tecniche

indirect ELISA: 1:25,000

N° accesso UniProt

P01008

Temperatura di conservazione

2-8°C

modifica post-traduzionali bersaglio

unmodified

Informazioni sul gene

human ... SERPINC1(462)

Descrizione generale

Antithrombin III (ATIII) is a small glycoprotein produced by the liver that functions as a serine protease inhibitor to block coagulation.

Antithrombin III is a 58kDa glycoprotein synthesized in the liver. It has two domains, a heparin-binding domain and target protease binding domain.

Immunogeno

human antithrombin III

Applicazioni

Anti-Antithrombin III antibody has been used in western blotting and antigenic assay.

Azioni biochim/fisiol

Antithrombin III is a serine protease inhibitor which affects many intrinsic and extrinsic blood coagulation pathways. It inactivates the function of thrombin and factor X in blood. Severe sepsis is caused due to lack of antithrombin III.

Stato fisico

Lyophilized from 0.01 M phosphate buffered saline, pH 7.2

Ricostituzione

Reconstitute with 2 mL deionized water.

Esclusione di responsabilità

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?

Try our Motore di ricerca dei prodotti.

Pittogrammi

GHS05

Avvertenze

Danger

Indicazioni di pericolo

H318

Consigli di prudenza

P280 - P305 + P351 + P338

Classi di pericolo

Eye Dam. 1

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Defects of splicing in antithrombin deficiency

de la Morena-Barrio M E, et al.

Research and practice in thrombosis and haemostasis, 1(2), 216-222 (2017)

Identification of Regulatory Mutations in SERPINC1 Affecting Vitamin D Response Elements Associated with Antithrombin Deficiency.

Mara Toderici et al.

PloS one, 11(3), e0152159-e0152159 (2016-03-24)

Antithrombin is a crucial anticoagulant serpin whose even moderate deficiency significantly increases the risk of thrombosis. Most cases with antithrombin deficiency carried genetic defects affecting exons or flanking regions of SERPINC1.We aimed to identify regulatory mutations inSERPINC1 through sequencing the

Antithrombin III in patients with severe sepsis

Eisele B, et al.

Intensive Care Medicine, 24(7), 663-672 (1998)

Contact pathway in surgical and transcatheter aortic valve replacement.

María Eugenia de la Morena-Barrio et al.

Frontiers in cardiovascular medicine, 9, 887664-887664 (2022-08-09)

Aortic valve replacement is the gold standard treatment for severe symptomatic aortic stenosis, but thrombosis of bioprosthetic valves (PVT) remains a concern. To analyze the factors involved in the contact pathway during aortic valve replacement and to assess their impact

Full-length antithrombin frameshift variant with aberrant C-terminus causes endoplasmic reticulum retention with a dominant-negative effect.

Carlos Bravo-Pérez et al.

JCI insight, 7(19) (2022-10-11)

Antithrombin, a major endogenous anticoagulant, is a serine protease inhibitor (serpin). We characterized the biological and clinical impact of variants involving C-terminal antithrombin. We performed comprehensive molecular, cellular, and clinical characterization of patients with C-terminal antithrombin variants from a cohort

Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.